The Asian Scientist 100
Can Li
Institution
University of Hong Kong
Country
Hong Kong
Field
Engineering
Li is a recipient of the 2023 Croucher Tak Wah Mak Innovation Award for his research exploring the limitations of digital computers in performing tasks accomplished by the human brain, including recognising faces, reasoning based on vague information, and learning from experience.
(Photo: University of Hong Kong)
AWARDS
- 2023 Croucher Tak Wah Mak Innovation Award
Related articles
What Humanoids Can Teach Us About Being Human
Why design a robot version of yourself? Asian Scientist Magazine picks the brain of world-leading robotics scientist, Professor Hiroshi Ishiguro, to find out.
The AI Spring Is Coming
Hon Hsiao-Wuen, managing director of Microsoft Research Asia, is excited about AI and robots, and explains why you should be too.
[INFOGRAPHIC] What You Need To Know About Immunotherapy
Our immune system protects us against a host of infections, but it can also be trained to seek out and destroy cancer.
Medicine’s New Stethoscope
Detecting cancers with a blood test sounds simple enough, but is it just hype or are liquid biopsies here to stay?
How To Win The Nobel Prize Of Supercomputing
Winning the ACM Gordon Bell Prize in High Performance Computing requires a team effort, says Professor Fu Haohuan, a member of the 12-man team that won the competition in 2016.
When Your Doctor Knows It All
IBM Watson is changing the practice of healthcare in both hospitals and homes with its ability to learn and apply huge volumes of information.
The Ocean Is Starting To Boil
Over the hundred years that they have been used, floating-point numbers have become so entrenched that replacing them would be like “boiling the ocean.” But Dr. John Gustafson believes he has done just that.
High Performance Healthcare
Thanks to all the data that is already available, the healthcare sector is ripe for a data-driven transformation. Here’s how supercomputers can make a difference.
When T Spells Trouble For Cancer
The world’s largest clinical trial of T-cells for cancer is being conducted by a Singapore-based biotech company, Tessa Therapeutics. Sim Shuzhen finds out more.









